These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33812767)

  • 1. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
    Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
    Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
    Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
    Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
    J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
    Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
    Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    Kearton S; Wills K; Bunting M; Blomfield P; James PA; Burke J
    Fam Cancer; 2018 Jul; 17(3):333-344. PubMed ID: 29039136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cragun D; Weidner A; Lewis C; Bonner D; Kim J; Vadaparampil ST; Pal T
    Cancer; 2017 Jul; 123(13):2497-2505. PubMed ID: 28182268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female
    Zimovjanova M; Bielcikova Z; Miskovicova M; Vocka M; Zimovjanova A; Rybar M; Novotny J; Petruzelka L
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
    Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
    Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
    Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
    Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
    Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Vaisman Y; Feldman D; Helpman L; Gitly M; Paluch Shimon S; Berger R; Cohen L; Narod SA; Friedman E
    Clin Genet; 2014 Jan; 85(1):68-71. PubMed ID: 23517234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
    Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the
    Jung SM; Ryu JM; Park HS; Park JS; Kang E; Lee S; Lee HB; Youn HJ; Yoo TK; Kim J; Lee JE; Han SA; Kim D; Kim SW;
    J Breast Cancer; 2020 Dec; 23(6):647-655. PubMed ID: 33408890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
    Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
    Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.